TheFly reported on April 13 that Mizuho reduced its price target on BSX to $90 from $115 while maintaining an Outperform ...

Boston Scientific heads into Q1 earnings with strong Cardiovascular momentum and steady MedSurg growth, as estimates point to ...

Boston Scientific BSX has raised its full-year 2025 guidance following robust first-quarter results and continued momentum across key growth areas. The company now anticipates net sales to grow ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Boston Scientific (BSX) is a stock that can certainly grab the ...

Shares of medical device company Boston Scientific (NYSE:BSX) jumped 4.4% in the morning session after the company reported strong third-quarter results that topped Wall Street's forecasts and raised ...

Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2025 results , with sales up 22.8% year on year to $5.06 billion. Guidance for next quarter’s revenue was optimistic at $4.97 billion ...

Boston Scientific Corp (NYSE:BSX) is one of Goldman Sachs top healthcare stocks. On March 4, TD Cowen reiterated that Boston Scientific Corp (NYSE:BSX) stock’s year-to-date decline appears overdone in ...

Boston Scientific is a global leader in medical devices, excelling in both MedSurg and Cardiovascular segments with consistent, industry-beating growth. Q1 2024 was a record quarter, with 21% YoY ...

Boston Scientific (NYSE:BSX) traded higher on Wednesday after the MedTech giant exceeded Street forecasts with its Q3 2025 results and boosted its full-year outlook following better-than-expected ...